PMID- 36127221
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221021
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 155
DP  - 2022 Nov
TI  - Application of dendritic cells in tumor immunotherapy and progress in the 
      mechanism of anti-tumor effect of Astragalus polysaccharide (APS) modulating 
      dendritic cells: a review.
PG  - 113541
LID - S0753-3322(22)00930-1 [pii]
LID - 10.1016/j.biopha.2022.113541 [doi]
AB  - Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that are 
      essential in mediating the body's natural and adaptive immune responses. The body 
      can regulate the function of DCs in various ways to enhance their antitumor 
      effects. In the tumour microenvironment (TME), antigen-specific T cell responses 
      are initiated through DC processing and delivery of tumour-associated antigens 
      (TAAs); conversely, tumour cells inhibit DC recruitment by releasing metabolites, 
      cytokines and other regulatory TME and function. Different subpopulations of DCs 
      exist in tumour tissues, and their functions vary. Insight into DC subgroups in 
      TME allows assessment of the effectiveness of tumour immunotherapy. Astragalus 
      polysaccharide (APS) is the main component of the Chinese herb Astragalus 
      membranaceus. The study found that the antitumor effects of APS are closely 
      related to DCs. APS can promote the expression of surface molecules CD80 and 
      CD86, promote the maturation of DCs, and activate CTL to exert antitumor effects. 
      We reviewed the application of DCs in tumor immunotherapy and the mechanism of 
      modulation of DCs by Astragalus polysaccharide to provide new directions and 
      strategies for tumor therapy and new drug development.
CI  - Copyright (c) 2022. Published by Elsevier Masson SAS.
FAU - Wang, Dong
AU  - Wang D
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China; Graduate School of 
      Tianjin University of traditional Chinese Medicine, Tianjin, China.
FAU - Cui, Qian
AU  - Cui Q
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China; Graduate School of 
      Tianjin University of traditional Chinese Medicine, Tianjin, China.
FAU - Yang, Yan Jie
AU  - Yang YJ
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China; Graduate School of 
      Tianjin University of traditional Chinese Medicine, Tianjin, China.
FAU - Liu, A Qing
AU  - Liu AQ
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China; Graduate School of 
      Tianjin University of traditional Chinese Medicine, Tianjin, China.
FAU - Zhang, Guan
AU  - Zhang G
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China; Graduate School of 
      Tianjin University of traditional Chinese Medicine, Tianjin, China.
FAU - Yu, Jian Chun
AU  - Yu JC
AD  - Department of Oncology, First Teaching Hospital, Tianjin University of 
      Traditional Chinese Medicine, National Clinical Research Center for Chinese 
      Medicine Acupuncture and Moxibustion, Tianjin 300193, China. Electronic address: 
      yujianchun2000@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220918
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Polysaccharides)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - Hepatitis B Antibodies/metabolism/pharmacology
MH  - Dendritic Cells
MH  - *Astragalus Plant
MH  - Polysaccharides/pharmacology/therapeutic use/metabolism
MH  - Immunotherapy
MH  - *Neoplasms/drug therapy/metabolism
MH  - Cytokines/metabolism
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Astragalus polysaccharide
OT  - DC subgroups
OT  - DC vaccine
OT  - Dendritic cells
OT  - Tumor microenvironm
COIS- Conflict of interest statement All authors disclosed no relevant relationships.
EDAT- 2022/09/21 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/09/20 22:05
PHST- 2022/07/02 00:00 [received]
PHST- 2022/08/09 00:00 [revised]
PHST- 2022/08/10 00:00 [accepted]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/09/20 22:05 [entrez]
AID - S0753-3322(22)00930-1 [pii]
AID - 10.1016/j.biopha.2022.113541 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Nov;155:113541. doi: 10.1016/j.biopha.2022.113541. Epub 
      2022 Sep 18.